Shares of CalciMedica Inc. (CALC) touched a new 52-week high of $6.40 last week, as investors look ahead to data related to the company's lead drug candidate, Auxora, in the coming months.
This clinical-stage biopharmaceutical company is developing calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The lead drug candidate, Auxora, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com